Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results are being presented today, June 15, from 5:30-7:00 p.m. CET in a poster session titled “Chronic lymphocytic leukemia and related disorders – Clinical” at the 24th Congress of the European Hematology Association (EHA) in Amsterdam. The poster, titled “Preliminary Results of a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor (BTKi) Vecabrutinib in B-Cell Malignancies,” Abstract No. PS1148, is available at www.sunesis.com.
“We are encouraged by the data presented today demonstrating vecabrutinib’s well-tolerated safety profile and evidence of clinical activity in CLL and other B-cell malignances,” said Dayton Misfeldt, Interim Chief Executive Officer of Sunesis. “Importantly, vecabrutinib’s median steady-state trough concentrations continue to increase with dose and are approaching levels expected to provide consistent BTK inhibition and greater clinical activity. We are currently dosing patients in the 200mg cohort and momentum in the trial continues as reflected by the robust pace of enrollment we’ve seen this year. We look forward to sharing data from the additional cohorts as we complete the Phase 1b and proceed to Phase 2 later this year.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.